Faculty Digital Archive

Archive@NYU >
Stern School of Business >
Finance Working Papers >

Please use this identifier to cite or link to this item: http://hdl.handle.net/2451/26478

Title: LIMITED ARBITRAGE AND SHORT SALES RESTRICTIONS: EVIDENCE FROM THE OPTIONS MARKETS
Authors: Ofeka, Eli
Richardson, Matthew
Whitelaw, Robert F.
Issue Date: 2002
Series/Report no.: FIN-02-034
Abstract: In this paper, we investigate empirically the well-known put-call parity no-arbitrage relation in the presence of short sale restrictions. We use a new and comprehensive sample of options on individual stocks in combination with a measure of the cost and difficulty of short selling, specifically the spread between the rate a short-seller earns on the proceeds from the sale relative to the normal rate (the rebate rate spread). We find statistically and economically significant violations of put-call parity that are strongly related to the rebate rate spread. Stocks with negative rebate rate spreads exhibit prices in the stock market that are up to 7.5% greater than those implied in the options market (for the extreme 1% tail). Even after accounting for transaction costs in the options markets, these violations persist and their magnitude appears to be related to the general level of valuations in the stock market. Moreover, the extent of violations of put-call parity and the rebate rate spread for individual stocks are significant predictors of future stock returns. For example, cumulative abnormal returns, net of borrowing costs, over a 2½- year sample period can exceed 70%. It is difficult to reconcile these results with rational models of investor behavior, and, in fact, they are consistent with the presence of overoptimistic irrational investors in the markets for some individual securities.
URI: http://hdl.handle.net/2451/26478
Appears in Collections:Finance Working Papers

Files in This Item:

File Description SizeFormat
02-34.pdf298.19 kBAdobe PDFView/Open

Items in Faculty Digital Archive are protected by copyright, with all rights reserved, unless otherwise indicated.

 

The contents of the FDA may be subject to copyright, be offered under a Creative Commons license, or be in the public domain.
Please check items for rights statements. For information about NYU’s copyright policy, see http://www.nyu.edu/footer/copyright-and-fair-use.html 
Valid XHTML 1.0 | CSS